Who Qualifies for Wegovy for Weight Loss?

Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy (semaglutide) approval by the FDA in 2021 created new pathways for weight management, yet many patients don't understand the full scope of eligibility. Qualification for semaglutide-based therapy involves multiple clinical factors beyond a simple number on a scale. PlexusDx provides compounded semaglutide injections starting at $149 per month, bringing this proven treatment within reach for qualifying candidates nationwide.

BMI Requirements and Weight Loss Qualification Thresholds

Body Mass Index (BMI) serves as the primary screening tool for GLP-1 eligibility, though it is not the only factor. Patients with a BMI of 30 or higher generally qualify, as do individuals with a BMI of 27 or higher who carry at least one weight-related health condition. Weight-related conditions include type 2 diabetes, hypertension, sleep apnea, and heart disease. A BMI calculation divides body weight in kilograms by height in meters squared, providing a standardized measure across diverse patient populations.

Qualifying candidates must also demonstrate commitment to lifestyle modification, including dietary changes and physical activity. Initial consultation involves reviewing medical history, current medications, and metabolic factors. PlexusDx evaluates each candidate to ensure semaglutide therapy aligns with individual health goals and reduces potential risks. The decision to start treatment remains collaborative between patient and healthcare provider.

Medical Conditions That Support Semaglutide Eligibility

Existing weight-related medical conditions strengthen the case for GLP-1 therapy qualification. Type 2 diabetes represents the most common comorbidity, as semaglutide simultaneously addresses blood sugar control and weight reduction through dual mechanisms. Cardiovascular disease, including prior heart attack or stroke, also qualifies patients because weight loss reduces cardiac risk. Hypertension, obstructive sleep apnea, fatty liver disease, and polycystic ovary syndrome (PCOS) each support medical necessity for treatment.

Metabolic dysfunction, characterized by insulin resistance or poor glucose tolerance, indicates GLP-1 responsiveness. Previous weight loss attempts using other methods strengthen eligibility documentation. PlexusDx reviews complete medical records to confirm that semaglutide injection or oral formulations represent appropriate next steps in weight management. Age, liver function, kidney function, and personal or family history of pancreatitis also inform safety assessment.

Age, Kidney Function, and Absolute Contraindications

Age alone does not disqualify patients, though kidney function requires careful monitoring in adults over 65 years old. Semaglutide undergoes minimal renal excretion, making it safer than many alternatives, but baseline kidney function assessment remains standard. Moderate to severe kidney disease may warrant dose adjustments or closer supervision. Liver function abnormalities also require evaluation, though compounded semaglutide generally remains tolerable in mild hepatic impairment.

Absolute contraindications include personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Patients with acute pancreatitis or gallbladder disease history require careful risk-benefit analysis. Pregnancy and breastfeeding are contraindications due to limited fetal exposure data. PlexusDx screens all candidates for these red flags during initial qualification review to ensure safe, appropriate treatment selection.

How PlexusDx Qualification Differs From Wegovy Brand Requirements

PlexusDx compounded semaglutide from licensed 503A pharmacies meets the same active pharmaceutical ingredient standards as brand Wegovy but operates under different regulatory pathways. Compounded medications allow providers greater flexibility in dosing schedules and formulation choices, enabling personalization based on individual response. Patients avoid insurance barriers and prior authorization delays common with brand drugs. PlexusDx serves all 50 states with no membership fees or insurance requirements, making qualification assessment streamlined and accessible.

The Precision Peptide Genetic Test—a $99 add-on after first month—maps 14 pathways and 150+ genetic insights to predict individual peptide responsiveness. Testing evaluates genetic variants in GLP1R, GIPR, FTO, and MC4R genes that influence weight loss trajectory and medication efficacy. This personalization tool helps PlexusDx optimize therapy selection, potentially identifying whether semaglutide injection, oral semaglutide, tirzepatide, or dual GLP-Squared compounds match individual genetic predispositions. HSA and FSA accounts cover all PlexusDx medications and testing, further reducing out-of-pocket burden for qualifying candidates.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the minimum BMI to qualify for semaglutide weight loss treatment?

A BMI of 30 or higher qualifies most candidates, while a BMI of 27 or higher qualifies patients with weight-related conditions like diabetes or hypertension. PlexusDx evaluates BMI alongside health history to confirm medical appropriateness. Your provider will review these criteria during initial consultation.

Can I qualify for semaglutide if I don't have type 2 diabetes?

Yes—semaglutide qualifies patients based on BMI and non-diabetic weight-related conditions including hypertension, sleep apnea, and cardiovascular disease. Many PlexusDx patients use semaglutide exclusively for weight management without diabetes. Clinical trial data shows sustained weight loss of 15-22% across diverse patient populations.

Does PlexusDx require insurance approval or prior authorization?

PlexusDx compounded semaglutide requires no insurance and no membership fees. Treatment starts at $149 per month, with HSA and FSA accounts accepted. Patients across all 50 states access medication without prior authorization delays, making qualification and initiation faster than brand-only pathways.

What medical conditions automatically disqualify me from semaglutide therapy?

Personal or family history of medullary thyroid cancer and Multiple Endocrine Neoplasia type 2 are absolute contraindications. Acute pancreatitis, pregnancy, and breastfeeding also exclude candidates. PlexusDx screens for these during qualification to ensure safe treatment selection and prevent harm.

How does the Precision Peptide Genetic Test improve my qualification and outcomes?

The Precision Peptide Genetic Test ($99 add-on) evaluates genetic variants in GLP1R, GIPR, FTO, and MC4R that predict semaglutide responsiveness and optimal therapy type. Patients with favorable GLP1R variants typically experience superior weight loss, while MC4R variants may indicate need for combination therapy. This genetic insight personalizes treatment selection and maximizes success probability.

Related Reading

• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss
• Wegovy Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.